Aug 11, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
Aug 8, 2023 8:00 am EDT Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
Jul 26, 2023 8:00 am EDT Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
Jul 10, 2023 5:19 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 27, 2023 8:00 am EDT Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
Jun 21, 2023 8:00 am EDT Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
Jun 12, 2023 8:00 am EDT Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023
May 24, 2023 4:05 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
May 2, 2023 8:30 am EDT Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator